KHK7580 + KRN1493
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Secondary Hyperparathyroidism
Conditions
Secondary Hyperparathyroidism
Trial Timeline
Sep 1, 2015 → Nov 1, 2016
NCT ID
NCT02549391About KHK7580 + KRN1493
KHK7580 + KRN1493 is a phase 2/3 stage product being developed by Kyowa Kirin for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT02549391. Target conditions include Secondary Hyperparathyroidism.
What happened to similar drugs?
13 of 20 similar drugs in Secondary Hyperparathyroidism were approved
Approved (13) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02549391 | Phase 2/3 | Completed |
Competing Products
20 competing products in Secondary Hyperparathyroidism